Hospital de São João

Running trials

• Not yet recruiting

  Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

  NCT07772544· Sociedade Portuguesa de Reumatologia· Source

• Recruiting

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

  NCT06680817· Hoffmann-La Roche· Source

• Active, not recruiting

  Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

  NCT05797740· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Active, not recruiting

  The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)

  NCT06416644· Hospital do Divino Espírito Santo de Ponta Delgada· Source

• Recruiting

  European Myeloma Network (EMN) Sample Project

  NCT06237803· European Myeloma Network B.V.· Source

• Recruiting

  Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  NCT05219617· Phase 3· SK Life Science, Inc.· Source

• Active, not recruiting

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  NCT04844606· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  LANDMARK Trial: a Randomised Controlled Trial of Myval THV

  NCT04275726· Meril Life Sciences Pvt. Ltd.· Source

• Active, not recruiting

  Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801· Frank G. Holz· Source

• Recruiting

  The European Paediatric Network for Haemophilia Management ( PedNet Registry)

  NCT02979119· PedNet Haemophilia Research Foundation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Crohn's disease1 recruiting
• Epilepsy1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

  NCT05126966· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

  NCT05649137· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Completed

  Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

  NCT04934800· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Takeda· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Baxalta now part of Shire· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hypertrophic cardiomyopathy13 works · 0 trials
• Myocarditis12 works · 0 trials
• Polycystic kidney disease4 works · 0 trials
• Fabry disease3 works · 0 trials